Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00122590
Recruitment Status : Terminated
First Posted : July 22, 2005
Last Update Posted : August 1, 2005
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by:
French National Agency for Research on AIDS and Viral Hepatitis

Tracking Information
First Submitted Date  ICMJE July 20, 2005
First Posted Date  ICMJE July 22, 2005
Last Update Posted Date August 1, 2005
Study Start Date  ICMJE July 2002
Primary Completion Date Not Provided
Current Primary Outcome Measures  ICMJE
 (submitted: July 28, 2005)
  • treatment failure defined as viral load greater than 200 copies/ml between week 16 (W16) and week 48 (W48) (confirmed by 2 samples spiked at least 15 days apart but no more than 45 days after virological failure, assayed by 50 copies/ml method)
  • toxicity related to PI, defined as adverse event grade 3 or 4 with ANRS quotation, renal colic, diarrhoea grade 2, or cholesterolemia over 10 times the normal value
Original Primary Outcome Measures  ICMJE
 (submitted: July 20, 2005)
  • treatment failure defined as viral load over 200 copies between W16 and W48 (confirmed by 2 samples spiked at least 15 days apart but no more than 45 days after virological failure, assayed by 50 copies/ml method)
  • or toxicity related to PI, defined as adverse event grade 3 or 4 with ANRS quotation, or renal colic, or diarrhoea grade 2, or cholesterolemia over 10 times the normal value
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 28, 2005)
  • virological failure: viral load over 200 copies/ml between W16 and W48 (confirmed by 2 samples spiked at least 15 days apart but no more than 45 days after virological failure, assayed by 50 copies/ml method)
  • toxicity related to PI: adverse events grade 3 or 4 with ANRS quotation, renal colic, diarrhoea grade 2, or cholesterolemia over 10 times the normal value
  • patients with trough plasma concentrations outside the therapeutic range at W24 and W48
  • concentration changes with dosage variation
  • time to obtain a viral load below 200 copies/ml
  • relationship between adverse events grade 3 or 4 related to PI and plasma concentration at week 2 (W2)
  • relationship between pharmacokinetic parameters and/or plasma concentrations and the drop of viral load between day 0 (D0) and W2 and between D0 and week 4 (W4)
  • relationship between pharmacokinetic parameters and viral mutations occurring during the treatment of patients with virological failure (over 1000 copies/ml after week 24 [W24])
  • PI pharmacokinetic parameter estimation and evaluation of variability
  • pharmacokinetic variability of nucleoside analogues at W2
  • intracellular concentration of nucleoside triphosphate derivatives at W2 (trough and maximum) and relationship between virological response and adverse events
  • relationship between inhibitory quotient of indinavir and virological response
Original Secondary Outcome Measures  ICMJE
 (submitted: July 20, 2005)
  • virological failure : viral load over 200 copies between W16 and W48 (confirmed by 2 samples spiked at least 15 days apart but no more than 45 days after virological failure, assayed by 50 copies/ml method)
  • Toxicity related to PI : adverse events grade 3 or 4 with ANRS quotation, or renal colic, or diarrhoea grade 2, or cholesterolemia over 10 times the normal value
  • patients with trough plasma concentrations outside the therapeutic range at W24 and W48
  • concentration changes with dosage variation
  • time to obtain a viral load below 200 copies/ml
  • Relationship between adverse events grade 3 or 4 related to PI and plasma concentration at W2
  • Relationship between pharmacokinetic parameters and/or plasma concentrations and the drop of viral load between D0 and W2 and between D0 and W4
  • Relationship between pharmacokinetic parameters and viral mutations occurring during the treatment of patients with virological failure (over 1000 copies/ml after W24)
  • PI pharmacokinetic parameter estimation and evaluation of variability
  • pharmacokinetic variability of nucleoside analogues at W2
  • intracellular concentration of nucleoside triphosphate derivatives at W2 (trough and maximum) and relationship between virological response and adverse events
  • relationship between inhibitory quotient of indinavir and virological response
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Evaluation of Therapeutic Drug Monitoring of Protease Inhibitors on Virologic Success and Tolerance of Highly Active Antiretroviral Therapy (HAART)
Official Title  ICMJE Prospective Trial to Evaluate How Therapeutic Drug Monitoring of Protease Inhibitors Increases Virologic Success and Tolerance of HAART (ANRS 111 COPHAR2)
Brief Summary This Cophar2 study is a trial which evaluates repeated early therapeutic drug monitoring, from weeks 2 to 24, after the initiation of HAART including either indinavir/r, lopinavir/r or the new 625 mg formulation of nelfinavir twice-a-day (bid). If trough concentrations were out of the range given for each protease inhibitor (PI), the PI dose was adjusted.
Detailed Description

Because of the large pharmacokinetic inter-patient variability of protease inhibitors (PI), therapeutic drug monitoring (TDM) of protease inhibitor (PI) has been proposed to improve efficacy and tolerance of PI-containing HAART. The objective of the Cophar2 trial is to evaluate the feasibility and the impact of an early therapeutic drug monitoring in PI-naive HIV-1 infected patients in order to warrant virological success and safety of HAART.

It is a prospective, open, multicenter trial with repeated early TDM (weeks 2, 8 or 16, 24) after the initiation of HAART including either indinavir/r (IDV), lopinavir/r (LPV) or the new 625 mg formulation of nelfinavir (NFV) bid. It was planned to include 99 PI-naïve HIV-1 infected patients over 18 years old, 33 for each PI. Concentrations were measured by HPLC in each center. If trough concentrations were out of the range of 150-500, 2500-7000 or 1500-5500 ng/ml for IDV, LPV and NFV respectively, the PI doses were adjusted possibly more than once during the first 24 weeks of follow-up. Adjustments were done by steps of one pill (200, 133/33 or 250 mg for IDV, LPV/r or NFV, respectively) bid. Failure of the strategy was defined by either two consecutive viral loads over 200 copies/ml between weeks 16 and 48, or a validated PI-related adverse event grade III or IV or a grade II diarrhoea or renal lithiasis. Patients without adverse events before week 16 were defined as assessable if they had at least the virological assessment of week 16.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE HIV Infections
Intervention  ICMJE
  • Drug: nelfinavir
  • Drug: lopinavir/r
  • Drug: indinavir
  • Drug: ritonavir
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Enrollment  ICMJE
 (submitted: July 20, 2005)
115
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE March 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients infected with HIV-1
  • Needing an antiretroviral treatment according to standard of care
  • HIV viral load greater than 1000 copies/ml
  • Beginning a treatment containing a PI (indinavir with or without ritonavir, nelfinavir, lopinavir + ritonavir) and 2 reverse transcriptase inhibitors
  • PI-naive
  • Antiretroviral treatment-naive or already treated with reverse transcriptase inhibitors but if the viral genotypic test does not show more than 2 major mutations (including T215Y/F, Q151M, M184V/I, V75M/S, L74V) and if 3 nucleoside analogues are still active except for didanosine.

Exclusion Criteria:

  • Pregnant women and nursing mothers
  • Acute HIV infection
  • Diabetes
  • Renal insufficiency with creatinine clearance below 30 ml/min
  • Cardiac insufficiency
  • Hepatic insufficiency with TP below 60%
  • Treatment with known interactions with PI
  • Chemotherapy against Kaposi's sarcoma, lymphoma, neoplasia
  • Treatment containing interferon (INF) or interleukin-2 (IL2) or HIV- immune vaccine
  • Treatment with hypolipemic drugs
  • Laxative treatment
  • Previous renal colic
  • Diarrhoea with more than 5 stools/day since one week
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00122590
Other Study ID Numbers  ICMJE ANRS111 COPHAR 2
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE French National Agency for Research on AIDS and Viral Hepatitis
Collaborators  ICMJE Hoffmann-La Roche
Investigators  ICMJE
Principal Investigator: Dominique Salmon, MD Service de Medecine Interne Hopital Cochin Paris
Study Chair: France Mentre, MD Inserm EMI 03 57
PRS Account French National Agency for Research on AIDS and Viral Hepatitis
Verification Date July 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP